🔥🐔 BizChicken 🐔🔥

Companies Similar to Seres Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Gain Therapeutics, Inc.

Gain Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Site-Directed Enzyme Enhancement Therapy platform

Gain Therapeutics, Inc. is a biotechnology company developing therapies for diseases caused by protein misfolding, focusing on rare genetic diseases and neurological disorders. It utilizes its proprietary technology to discover and develop molecules targeting misfolded proteins.

Tags: allosteric regulation, biotechnology, neurological disorders, protein misfolding, rare genetic diseases

Symbol: GANX

Recent Price: $2.18

Industry: Biotechnology

CEO: Mr. Gene Mack M.B.A.

Sector: Healthcare

Employees: 29

Address: 4800 Montgomery Lane, Bethesda, MD 20814

Phone: 301 500 1556

Last updated: 2024-12-31

Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

CAP-1002

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing transformative cell and exosome-based therapeutics aimed at treating and preventing a range of diseases and disorders. Their lead candidate, CAP-1002, is designed for Duchenne muscular dystrophy and cytokine storm interventions.

Tags: COVID-19, Duchenne muscular dystrophy, biotechnology, cell therapy, therapeutics

Symbol: CAPR

Recent Price: $13.76

Industry: Biotechnology

CEO: Dr. Linda Marbán Ph.D.

Sector: Healthcare

Employees: 101

Address: 10865 Road to the Cure, San Diego, CA 92121

Phone: 310 358 3200

Leadership

  • Linda Marbán, Ph.D., Chief Executive Officer and Director
  • Kristi A. H. Elliott, Ph.D., Chief Science Officer
  • AJ Bergmann, M.B.A., Chief Financial Officer
  • Karen G. Krasney, J.D., Executive Vice President and General Counsel
  • Mark Awadalla, Vice President of Clinical Operations
  • Jonathan Tayco, Vice President of Program Management and Business Operations
  • Minghao Sun, Ph.D., Vice President of Research and Product Development
  • Yushi Feng, Ph.D., Vice President of Regulatory Affairs
  • Frank Litvack M.D., FACC, Executive Chairman
  • Paul G. Auwaerter, M.D., M.B.A., FIDSA, Director
  • Earl M. (Duke) Collier Jr., Director
  • George W. Dunbar, Jr., Director
  • Philip J. Gotwals, Ph.D., Director
  • Michael Kelliher, Director
  • David B. Musket, Director
  • Karimah Es Sabar, Director

Last updated: 2024-12-31

Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

XMT-1592

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing antibody drug conjugates (ADC) for treating cancer patients with unmet needs. It specializes in ADC products like XMT-1592 and has strategic partnerships for the advancement of its innovative therapeutics.

Tags: ADC, XMT-1592, biopharmaceutical, cancer treatment, clinical trials, partnerships

Symbol: MRSN

Recent Price: $1.42

Industry: Biotechnology

CEO: Dr. Martin H. Huber M.D.

Sector: Healthcare

Employees: 123

Address: 840 Memorial Drive, Cambridge, MA 02139

Phone: 617 498 0020

Leadership

  • David Mott, Chairman of the Board
  • Lawrence Alleva, Retired Partner, PriceWaterhouseCoopers
  • Willard H. Dere, MD, Professor Emeritus of Internal Medicine, University of Utah
  • Allene M. Diaz, Independent Commercial Strategy and Portfolio Management Consultant, AMD Consulting
  • Andrew Hack MD, PhD, Managing Director, Bain Capital Life Sciences
  • Kristen M. Hege, MD, Retired Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb Company
  • Anna Protopapas, Chair of the board of directors of Nuvalent
  • Martin Huber, MD, President and Chief Executive Officer

Last updated: 2024-12-31

Seres Therapeutics, Inc.

Seres Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

SER-109

Seres Therapeutics, Inc. is a microbiome therapeutics platform company focused on developing bacterial consortia that interact with host cells and tissues to treat diseases, including SER-109 for clostridium difficile infection.

Tags: bacterial consortia, biotechnology, clinical trials, microbiome, therapeutics

Symbol: MCRB

Recent Price: $0.83

Industry: Biotechnology

CEO: Mr. Eric D. Shaff M.B.A.

Sector: Healthcare

Employees: 233

Address: 200 Sidney Street, Cambridge, MA 02139

Phone: 617 945 9626

Last updated: 2024-12-31

Spero Therapeutics, Inc.

Spero Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Tebipenem pivoxil hydrobromide (HBr), SPR206, SPR720

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States.

Tags: MDR infections, antibiotics, biopharmaceutical, clinical-stage, healthcare, rare diseases

Symbol: SPRO

Recent Price: $1.02

Industry: Biotechnology

CEO: Mr. Satyavrat Shukla C.F.A.

Sector: Healthcare

Employees: 46

Address: 675 Massachusetts Avenue, Cambridge, MA 02139

Phone: 857 242 1600

Leadership

  • Sath Shukla, President and Chief Executive Officer
  • Esther Rajavelu, Chief Financial Officer and Chief Business Officer
  • Timothy Keutzer, Chief Operating Officer
  • James P. Brady, Chief Human Resource Officer
  • Ankit Mahadevia, MD, Chairperson
  • Cynthia Smith, Compensation Committee Chair
  • Frank E. Thomas, Audit Committee Chair
  • Patrick Vink, MD, Nominating and Corporate Governance Chair
  • Milind Deshpande, PhD, Nominating and Corporate Governance Committee Member, Audit Committee Member, and Development Committee Member
  • Scott Jackson, Nominating and Corporate Governance Member and Audit Committee Member
  • John C. Pottage, Jr., M.D., Development Committee Chair
  • Kathleen Tregoning, Compensation Committee Member

Last updated: 2024-12-31

Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Immuno Phage platform

Sensei Biotherapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of immunotherapies for cancer, leveraging platforms such as Immuno Phage and Tumor Microenvironment Activated Biologics.

Tags: bacteriophage, biopharmaceutical, cancer treatment, immunotherapy, monoclonal antibodies

Symbol: SNSE

Recent Price: $0.48

Industry: Biotechnology

CEO: Mr. John K. Celebi M.B.A.

Sector: Healthcare

Employees: 28

Address: 451 D Street, Rockville, MD 02210

Phone: 240 243 8000

Last updated: 2024-12-31

Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. logo
Market Cap: High
Employees: Lowest

antibody therapeutics

Spyre Therapeutics, Inc. is a biotechnology company focusing on antibody therapeutics for treating inflammatory bowel disease, using advanced engineering and precision medicine.

Tags: antibody therapeutics, biotechnology, inflammatory bowel disease, precision medicine

Symbol: SYRE

Recent Price: $22.54

Industry: Biotechnology

CEO: Dr. Cameron Turtle DPHIL, Ph.D.

Sector: Healthcare

Employees: 50

Address: 221 Crescent Street, Waltham, MA 02453

Phone: 617 651 5940

Last updated: 2024-12-31

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, RNA-targeted therapeutics, biopharmaceutical, gene therapy, rare diseases

Symbol: SRPT

Recent Price: $121.19

Industry: Biotechnology

CEO: Mr. Douglas S. Ingram Esq.

Sector: Healthcare

Employees: 1314

Address: 215 First Street, Cambridge, MA 02142

Phone: 617 274 4000

Leadership

  • Douglas S. Ingram, President and Chief Executive Officer
  • Bilal Arif, Executive Vice President, Chief Technical Operations Officer
  • Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
  • Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
  • Ian M. Estepan, Executive Vice President, Chief Financial Officer
  • Dallan Murray, Executive Vice President, Chief Customer Officer
  • Alison Nasisi, Executive Vice President, Chief People Officer
  • Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
  • Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
  • M. Kathleen Behrens, PhD, Chairwoman
  • Richard J. Barry,
  • Kathryn Boor, PhD,
  • Michael Chambers,
  • Deirdre Connelly,
  • Stephen L. Mayo, PhD,
  • Claude Nicaise, MD,
  • Hans Wigzell, MD, PhD,
  • John C. Martin, PhD (In Memoriam),
  • Annemieke Aartsma-Rus, PhD,
  • Carsten Bönnemann, MD,
  • Joy Cavagnaro, PhD, DABT, Fellow ATS,
  • Kay Davies, PhD, DBE FMedSci FRS,
  • Steven Gray, PhD,
  • Angela J. Russell, DPhil,

Last updated: 2024-12-31

Biomerica, Inc.

Biomerica, Inc. logo
Market Cap: Lowest
Employees: Low

diagnostic and therapeutic products

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures, and markets diagnostic and therapeutic products for medical conditions and diseases worldwide, focusing on gastrointestinal diseases, food intolerances, and diabetes.

Tags: biomedical, diabetes, diagnostic, food intolerances, gastrointestinal, therapeutic

Symbol: BMRA

Recent Price: $0.31

Industry: Medical - Devices

CEO: Mr. Zackary S. Irani

Sector: Healthcare

Employees: 64

Address: 17571 Von Karman Avenue, Irvine, CA 92614

Phone: 949 645 2111

Last updated: 2024-12-31

Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

rezafungin acetate

Cidara Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology. Their lead product candidate is rezafungin acetate, a novel echinocandin antifungal for treating invasive fungal infections.

Tags: Cloudbreak platform, anti-infectives, antifungal, biotechnology, infectious diseases, oncology, rezafungin acetate

Symbol: CDTX

Recent Price: $25.25

Industry: Biotechnology

CEO: Dr. Jeffrey L. Stein Ph.D.

Sector: Healthcare

Employees: 69

Address: 6310 Nancy Ridge Drive, San Diego, CA 92121

Phone: 858 752 6170

Last updated: 2024-12-31

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CTX-009, CTX-471, CTX-8371

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.

Tags: CTX-009, CTX-471, CTX-8371, antibody therapeutics, biopharmaceutical, clinical stage, oncology

Symbol: CMPX

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Employees: 32

Address: 80 Guest Street, Boston, MA 02135

Phone: 617 500 8099

Last updated: 2024-12-31

Erasca, Inc.

Erasca, Inc. logo
Market Cap: Medium
Employees: Low

ERAS-007, ERAS-601, ERAS-801

Erasca, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

Tags: ERAS-007, ERAS-601, ERAS-801, RAS/MAPK, biopharmaceutical, cancers

Symbol: ERAS

Recent Price: $2.55

Industry: Biotechnology

CEO: Dr. Jonathan E. Lim M.D.

Sector: Healthcare

Employees: 126

Address: 10835 Road to the Cure, San Diego, CA 92121

Phone: 858 465 6511

Last updated: 2024-12-31

Keros Therapeutics, Inc.

Keros Therapeutics, Inc. logo
Market Cap: High
Employees: Low

KER-050

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for hematological and musculoskeletal disorders. Their lead product candidate, KER-050, targets cytopenias, including anemia and thrombocytopenia.

Tags: biopharmaceutical, clinical-stage, cytopenias, hematological disorders, musculoskeletal disorders

Symbol: KROS

Recent Price: $15.64

Industry: Biotechnology

CEO: Dr. Jasbir S. Seehra Ph.D.

Sector: Healthcare

Employees: 149

Address: 99 Hayden Avenue, Lexington, MA 02421

Phone: 617 314 6297

Leadership

  • Jasbir Seehra, Ph.D., Board Member
  • Keith Regnante, M.B.A., Chief Financial Officer
  • Christopher Rovaldi, President, Chief Operating Officer
  • Esther Cho, J.D., Senior Vice President, General Counsel
  • John Oram, M.B.A., Senior Vice President, Program and Portfolio Management
  • Robin Wagner, Senior Vice President, Human Resources
  • Carl L. Gordon, Ph.D., C.F.A., Board Member
  • Jean-Jacques Bienaimé, M.B.A., Lead Independent Director
  • Nima Farzan, M.B.A., Board Member
  • Mary Ann Gray, Ph.D., Board Member
  • Tomer Kariv, J.D., Board Member
  • Julius Knowles, M.B.A., Board Member
  • Ran Nussbaum, Board Member
  • Alpna Seth, Ph.D., Board Member

Last updated: 2024-12-31

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. logo
Market Cap: High
Employees: Low

novel small molecule therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.

Tags: IRAK4 program, autoimmune diseases, biopharmaceutical, immunology, inflammation, oncology, protein degradation, therapeutics

Symbol: KYMR

Recent Price: $39.32

Industry: Biotechnology

CEO: Dr. Nello Mainolfi M.D., Ph.D.

Sector: Healthcare

Employees: 184

Address: 200 Arsenal Yards Boulevard, Watertown, MA 02472

Phone: 857 285 5300

Leadership

  • Nello Mainolfi, Ph.D., Founder, President & CEO
  • Jeremy Chadwick, Ph.D., Chief Operating Officer
  • Ellen Chiniara, JD, Chief Legal Officer and Corporate Secretary
  • Jared Gollob, MD, Chief Medical Officer
  • Bruce Jacobs, CFA, MBA, Chief Financial Officer
  • Karen Weisbach, Head of People and Culture
  • Juliet Williams, Ph.D., Head of Research
  • Bruce Booth, DPhil, Chairman and Co-Founder
  • Felix J. Baker, PhD, Lead Independent Director
  • Jeff Albers, JD, MBA,
  • Pamela Esposito, PhD,
  • Gorjan Hrustanovic, PhD,
  • John Maraganore, PhD,
  • Leigh Morgan,
  • Victor Sandor, MDCM,
  • Elena Ridloff, CFA,

Last updated: 2024-12-31

Summit Therapeutics Inc.

Summit Therapeutics Inc. logo
Market Cap: Highest
Employees: Low

ridinilazole

Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines to treat infectious diseases, with a lead product candidate called ridinilazole in Phase III clinical trials for Clostridioides difficile infection (CDI).

Tags: Clostridioides difficile, antibiotic, biopharmaceutical, clinical trials, infectious diseases

Symbol: SMMT

Recent Price: $17.89

Industry: Biotechnology

CEO: Mr. Robert W. Duggan

Sector: Healthcare

Employees: 105

Address: One Broadway, Cambridge, MA 02142

Phone: 617 514 7149

Leadership

  • Bob Duggan, CEO & Chairman
  • Dr. Maky Zanganeh, CEO & President
  • Dave Gancarz, Chief Business & Strategy Officer
  • Dr. Urte Gayko, Chief Regulatory, Quality & Pharmacovigilance Officer
  • Dr. Fong Clow, Chief Biometrics Officer
  • Shelley D Spray, Chief Education & Brand Officer
  • Dr. Allen S. Yang, Chief Medical Officer
  • Bhaskar Anand, Head of Finance and Chief Accounting Officer
  • Dr. Betty Chang, Head of Research, Oncology & Inflammation
  • Dr. Andy Dwyer, Head of CMC & Supply Chain
  • Dr. Noam Frey, SVP, Global Medical Affairs
  • Pawan Parihar, Head of Information Technology
  • Dr. Juthamas Sukbuntherng, Head of Clinical Pharmacology & DMPK
  • Robert W. Duggan, CEO & Chairman of the Board
  • Dr. Mahkam (Maky) Zanganeh, CEO, President & Director
  • Manmeet Soni, Chief Operating Officer, Chief Financial Officer & Director
  • Kenneth A. Clark, Lead Independent Director
  • Dr. Robert Booth, Non-Executive Director
  • Dr. Alessandra Cesano, Non-Executive Director
  • Dr. Yu (Michelle) Xia, Director
  • Dr. Mostafa Ronaghi, Non-Executive Director
  • Jeff Huber, Non-Executive Director

Last updated: 2024-12-31

Shattuck Labs, Inc.

Shattuck Labs, Inc. logo
Market Cap: Lowest
Employees: Low

SL-172154

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States, with its lead product candidate being SL-172154.

Tags: autoimmune disease, biotechnology, cancer treatment, clinical trials, therapeutics

Symbol: STTK

Recent Price: $1.17

Industry: Biotechnology

CEO: Dr. Taylor H. Schreiber M.D., Ph.D.

Sector: Healthcare

Employees: 75

Address: 500 West 5th Street, Austin, TX 78703

Phone: 512 900 4690

Last updated: 2024-12-31

Verve Therapeutics, Inc.

Verve Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

VERVE-101

Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.

Tags: VERVE-101, biotechnology, cardiovascular diseases, gene editing, genetic medicines

Symbol: VERV

Recent Price: $5.54

Industry: Biotechnology

CEO: Dr. Sekar Kathiresan M.D.

Sector: Healthcare

Employees: 255

Address: 500 Technology Square, Cambridge, MA 02139

Phone: 617 603 0070

Leadership

  • Andrew Ashe, President, Chief Operating Officer and General Counsel
  • Victoria Bartlett, Vice President, Program and Alliance Management
  • Dan Balian, Associate Director, Supply Chain Management
  • Allen Barrett, Director, Corporate Counsel

Last updated: 2024-12-31

Theriva Biologics, Inc.

Theriva Biologics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SYN-004, SYN-020, VCN-01

Theriva Biologics Inc. is a clinical-stage company developing therapeutics to address diseases with high unmet needs, including SYN-004 for preventing microbiome damage and SYN-020 for treating GI and systemic diseases.

Tags: biologics, biopharmaceutical, clinical-stage, disease treatment, microbiome, therapeutics

Symbol: TOVX

Recent Price: $1.50

Industry: Biotechnology

CEO: Mr. Steven A. Shallcross CPA

Sector: Healthcare

Employees: 22

Address: 9605 Medical Center Drive, Rockville, MD 20850

Phone: 301 417 4364

Last updated: 2024-12-31

Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc. logo
Market Cap: Lowest
Employees: Lowest

CP101

Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company developing a novel class of orally administered biological drugs, with a lead candidate CP101 in Phase 3 trials for recurrent Clostridioides difficile infection, and a pipeline for other conditions.

Tags: biological drugs, biotechnology, clinical-stage, microbiome, therapeutics

Symbol: FNCH

Recent Price: $10.87

Industry: Biotechnology

CEO: Mr. Matthew P. Blischak J.D.

Sector: Healthcare

Employees: 1

Address: 200 Inner Belt Road, Somerville, MA 02143

Phone: 617 229 6499

Last updated: 2024-12-31

Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SLS-002, SLS-005, SLS-006, SLS-007, SLS-008, SLS-004, SLS-010

Seelos Therapeutics, Inc. is focused on developing and commercializing therapeutics for central nervous system, respiratory, and other disorders, with lead programs targeting major depressive disorders, amyotrophic lateral sclerosis, Sanfilippo syndrome, and Parkinson's disease.

Tags: ALS, Parkinson's disease, Sanfilippo syndrome, biopharmaceutical, central nervous system, major depressive disorder, respiratory disorders, therapeutics

Symbol: SEEL

Recent Price: $0.37

Industry: Biotechnology

CEO: Dr. Raj Mehra J.D., Ph.D.

Sector: Healthcare

Employees: 8

Address: 300 Park Avenue, New York, NY 10022

Phone: 646 293 2100

Last updated: 2024-12-31